Pharmacokinetics and comparative bioavailability study of two clarithromycin suspensions following administration of a single oral dose to healthy volunteers

Arzneimittel-Forschung/Drug Research

Volumn 59, Issue 8, 2009, Pages 429-432

  Zakeri Milani, Parvin ^a,b   Valizadeh, Hadi ^a,c   Ghanbarzadeh, Saeed ^a   Nemati, Mahboob ^a,d  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

CAS 81103 11 9; Clarithromycin, bioavailability, bioequivalence, pharmacokinetics; Klarexir ; Macrolide antibiotic

Indexed keywords

CLARITHROMYCIN;

AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG FORMULATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; TIME TO MAXIMUM PLASMA CONCENTRATION; ULTRAVIOLET RADIATION;

EID: 69249118531     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1296419     Document Type: Article

References (12)

1. Guay DR, Gustavson LE, Devcich KJ, Zhang J, Cao G, Olson CA. Pharmacokinetics and tolerability of extended-release clarithromycin. Clin Ther. 2001;23(4):566-577
2. Nash KA. Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38). Antimicrob Agents Chemother. 2003;47(10):3053-3060
3. Andini N, Nash KA. Intrinsic macrolide resistance of the Mycobacteriumtuberculosis complex is inducible. Antimicrob Agents Chemother. 2006;50(7):2560-2562 (Pubitemid 43993206)
4. Brown BA, Wallace RJ, Jr., Onyi GO. Activities of clarithromycin against eight slowly growing species of nontuberculous mycobacteria, determined by using a broth microdilution MIC system. Antimicrob Agents Chemother. 1992;36(9):1987-1990
5. Fernandes PB, Hardy DJ, McDaniel D, Hanson CW, Swanson RN. In vitro and in vivo activities of clarithromycin against Mycobacterium avium. Antimicrob Agents Chemother. 1989;33(9):1531-1534
6. Mor N, Esfandiari A. Synergistic activities of clarithromycin and pyrazinamide against Mycobacterium tuberculosis in human macrophages. Antimicrob Agents Chemother. 1997;41(9):2035-2036 (Pubitemid 27383254)
7. Sweetman SC. Martindale The complete Drug Reference. London: The Pharmaceutical Press; 2007.
8. Ferrero JL, Bopp BA, Marsh KC, Quigley SC, Johnson MJ, Anderson DJ, Lamm JE, Tolman KG, Sanders SW, Cavanaugh JH, et al. Metabolism and disposition of clarithromycin in man. Drug Metab Dispos. 1990;18(4):441-446
9. Guay DR, Craft JC. Overview of the pharmacology of clarithromycin suspension in children and a comparison with that in adults. Pediatr Infect Dis J. 1993;12(12 Suppl 3):S106-11.
10. Amini H, Ahmadiani A. Sensitive determination of clarithromycin in human plasma by high-performance liquid chromatography with spectrophotometric detection. J Chromatogr B Analyt Technol Biomed Life Sci. 2005;817(2)193-197 (Pubitemid 40430983)
11. Zakeri-Milani P, Valizadeh H, Islambulchilar Z. Comparative bioavailability study of two cefixime formulations administered orally in healthy male volunteers. Arzneimittelforschung. 2008;58(2):97-100. (Pubitemid 351346430)
12. Guidance for industry, bioavailability and bioequivalence studies for orally administered drug products; General considerations. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Reserch (CDER), July 2002 BP.